Attenuating Macrophage M2 Polarization through COX-2 Inhibition
COX-2 Inhibitors as Anti-Breast cancer modality
978-620-0-09420-9
6200094209
80
2019-05-14
39.90 €
eng
https://images.our-assets.com/cover/230x230/9786200094209.jpg
https://images.our-assets.com/fullcover/230x230/9786200094209.jpg
https://images.our-assets.com/cover/2000x/9786200094209.jpg
https://images.our-assets.com/fullcover/2000x/9786200094209.jpg
M2-polarized macrophages are well known for their pro-tumor functions. Owing to their established role in potentiating tumor-neovasculogenesis and metastasis, TAMs have emerged as promising target for anti-cancer immunotherapy. . Hindering macrophage polarization towards a pro-tumor M2 phenotype, or better still reprogramming the M2 like TAMs towards M1 subtype is being considered a beneficial anti-cancer strategy. Furthermore, sizeable body of data indicates for participation of cyclooxygenase-2 (COX-2) in macrophage polarization. Concordantly, inhibition of COX-2 is associated with impaired macrophage polarization. Prompted by this in the current study we decided to explore if inhibition of COX-2 activity via chemical inhibitors may prevent hypoxic cancer cell induced M2-polarization of macrophages. We observed that treatment with Etoricoxib and Flunixin meglumine, established selective and non-selective inhibitors of COX-2 respectively, markedly inhibited hypoxic cancer cell induced of M2-polarization of macrophages thereby indicating for usage of COX-2 inhibition as possible anti-cancer treatment modality.
https://morebooks.de/books/pt/published_by/lap-lambert-academic-publishing/47/products
Farmácia
https://morebooks.de/store/pt/book/attenuating-macrophage-m2-polarization-through-cox-2-inhibition/isbn/978-620-0-09420-9